What changed from existing technology?
This study compared three different tests to measure levels of two arthritis drugs and antibodies against them in patient blood samples.
The study is the first to directly compare the performance of three different assays for measuring drug concentrations and anti-drug antibodies in arthritis patients.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
Drug concentrations and anti-drug antibodies in patients with arthritis treated with infliximab and adalimumab - comparison of three assays. This study
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings may help guide clinical decisions about drug monitoring and treatment adjustments in arthritis patients.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.